Search results for "Thromboprophylaxis"
Very elderly patients can benefit from well-managed vitamin K antagonist thromboprophylaxis, study suggests
Adequate management of vitamin K antagonist (VKA) therapy in trained centers allowed very old and frail patients to benefit from VKA thromboprophylaxis, an Italian study concluded.
https://immattersacp.org/weekly/archives/2011/08/09/4.htm
9 Aug 2011
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022
Postexposure prophylaxis drug, vaccine complications, and anticoagulation in COVID-19
A monoclonal antibody combination was effective for postexposure prophylaxis and received emergency use authorization. A study investigated postvaccine myocarditis and pericarditis, and effects of full-dose anticoagulation differed by whether patients were critically ill.
https://immattersacp.org/weekly/archives/2021/08/10/1.htm
10 Aug 2021
Non-vitamin K oral anticoagulants appear superior to vitamin K antagonists in early-stage CKD
An accompanying editorial said that the current review supports a superior benefit profile of non-vitamin K oral anticoagulants (NOACs) in patients with atrial fibrillation and early-stage chronic kidney disease (CKD).
https://immattersacp.org/weekly/archives/2019/07/16/2.htm
16 Jul 2019
COVID-19 flu guidance, data on convalescent plasma, cardiac effects, and clot risk
Flu testing and treatment advice came from the NIH, convalescent plasma failed in a new trial, tocilizumab had mixed results, and remdesivir got full approval, among other COVID-19 news.
https://immattersacp.org/weekly/archives/2020/10/27/1.htm
27 Oct 2020
Clarification to a previous issue
In last week's ACP InternistWeekly, a story on thromboprophylaxis referred to vitamin K agonists instead of vitamin K antagonists.
https://immattersacp.org/weekly/archives/2011/08/16/10.htm
16 Aug 2011
Low-molecular-weight heparin may not prevent VTE after knee arthroscopy or lower-leg casting, studies find
The Prevention of Thrombosis after Knee Arthroscopy (POT-KAST) and the Prevention of Thrombosis after Lower Leg Plaster Cast (POT-CAST) trials used the same methods and design to compare a prophylactic dose of low-molecular-weight heparin or no anticoagulant therapy.
https://immattersacp.org/weekly/archives/2016/12/13/4.htm
13 Dec 2016
AHA statement describes prevention, treatment of the postthrombotic syndrome
A new scientific statement from the American Heart Association on the postthrombotic syndrome offers evidence-based prevention, diagnosis, and treatment strategies for inpatient and outpatient care.
https://immattersacp.org/weekly/archives/2014/09/30/5.htm
30 Sep 2014
Aspirin may be noninferior to dalteparin for VTE prophylaxis following hip replacements
Aspirin therapy for 28 days may be a reasonable alternative to low-molecular-weight heparin for extended venous thromboembolism (VTE) prophylaxis among hip replacement patients who have already received low-molecular-weight heparin for 10 days, a study found.
https://immattersacp.org/weekly/archives/2013/06/04/5.htm
4 Jun 2013